Más Dermatol. 2026;56:17-21 doi:10.5538/1887-5181.2026.56.17 21 NOVEDADES EN DERMATOLOGÍA Novedades en el tratamiento de la urticaria crónica Navarro Triviño FJ BIBLIOGRAFÍA 1. Kolkhir P, Salameh P, Zajac M, Kasperska-Zajac A, Giménez-Arnau A, Puértolas M, et al. Unmet needs in treatment escalation for chronic spontaneous urticaria: findings from the CURE Registry. Allergy. 2026. [En prensa]. 2. Kaplan AP, Ferrer Puga M, Sabaté-Brescó M. Endotypes in chronic spontaneous urticaria. J Allergy Clin Immunol. 2026;S0091-6749(26)00338-6. 3. Zuberbier T, Ansari ZAH, Latiff AHA, Abuzakouk MM, Agcaoili-De Jesús MS, Agondi RC, et al. The international guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2026. [En prensa]. 4. Grattan C, Dytyatkovska Y, Springer M, Ratkova M, Krusheva B, Krupa-Borek I, et al. Efficacy and safety of CT-P39, an omalizumab biosimilar, in chronic spontaneous urticaria: 16-week follow-up study. Clin Transl Allergy. 2025;15(6): e70069. 5. Jang M, Lee J, Yi S, Kwon TS. Budget impact of introducing an omalizumab biosimilar in 23 European countries. J Med Econ. 2025;28(1):1639-50. 6. Jia F, Zhao Q, Shi P, Liu H, Zhang F. Dupilumab: advances in the off-label usage of IL4/IL13 antagonist in dermatoses. Dermatol Ther. 2022;35(12):e15924. 7. Casale TB, Saini SS, Ben-Shoshan M, Giménez-Arnau AM, Bernstein JA, Hayama K, et al. Dupilumab in patients with chronic spontaneous urticaria: phase 3 LIBERTY-CSU CUPID randomized clinical trials. JAMA Dermatol. 2026;162(4):350-8. 8. Naassan S, Søndergaard MB, Porsbjerg C, Lorentsen RD, Thomsen SF. Dupilumab for chronic spontaneous urticaria with comorbid type 2 inflammatory conditions: case report and systematic review of the literature. Case Rep Dermatol. 2026;18(1):160-9. 9. Tsuchiya T, Takahashi T, Ikuno Y, Yamada M, Yamaguchi A, Arakawa A, et al. Type IIb chronic spontaneous urticaria refractory to omalizumab and dupilumab successfully and rapidly treated with cyclosporine. J Dermatol. 2026;53(3): e197-8. 10. Khan SA, Qadir A, Khan A, Kour S, Husain A. Chemistry, pharmacology and spotlight on the clinical trials of remibrutinib: a first in class, oral Bruton’s tyrosine kinase (BTK) inhibitor for chronic spontaneous urticaria. Mol Divers. 2026. [En prensa]. 11. Labrador-Horrillo M, Cenni B, Ferrer Puga M. A new drug target in allergic diseases: Bruton tyrosine kinase. J Investig Allergol Clin Immunol. 2026;36(3):170-84. 12. Muñoz M, Kiefer LA, Pereira MP, Bizjak M, Maurer M. New insights into chronic inducible urticaria. Curr Allergy Asthma Rep. 2024;24(8):457-69. 13. Maurer M, Metz M, Brehler R, Hillen U, Jakob T, Mahler V, et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence. J Allergy Clin Immunol. 2018;141(2):638-49. 14. Meara EM, Antaya RJ. Resolution of refractory cholinergic urticaria in a child treated with dupilumab. Pediatr Dermatol. 2026;43(2):479-80. 15. Sher M, Mimouni D, Levi A. Solar urticaria successfully treated with remibrutinib. J Allergy Clin Immunol Pract. 2026;S2213-2198(26)00416-2. 16. Zhu Y, Zhang W, Wang D, Chen S, Shao Y, Peng L, et al. Real-world outcomes and tolerability of Janus kinase inhibitors in chronic spontaneous urticaria and chronic inducible urticaria: a single-center retrospective study. J Am Acad Dermatol. 2026;95(1):166-9. 17. Wu K, Liu J. The MRGPRX2 paradigm shift: redefining mast cell activation pathways in chronic urticaria. Allergol Select. 2026;10(1):52-62. 18. Maurer M, Metz M, Anderson J, Talreja N, Young D, Crowley E, et al. Anti-KIT barzolvolimab for chronic spontaneous urticaria. Allergy. 2025;80(8):2178-86.
RkJQdWJsaXNoZXIy MTAyMDQzMg==